AstraZeneca - International Biopharmaceutical Industry

news

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug tha...

9 May 2022 news AstraZeneca | breast

Continue Reading →

news

AstraZeneca, Daiichi press rivals with new results for breast cancer drug

Dive Brief: AstraZeneca and Daiichi Sankyo's antibody drug Enhertu could become standard treatment for a large group of breast cancer patients following Phase 3 st...

24 February 2022 news AstraZeneca | breast

Continue Reading →

news

Amgen partners with Arrakis to develop drugs aimed at RNA

Dive Brief: Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, Massa...

14 January 2022 news AstraZeneca | Drugs

Continue Reading →

news

AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug

AstraZeneca is betting that Ionis' second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn't. Ionis developed Tegsedi for years...

10 December 2021 news AstraZeneca | ATTR

Continue Reading →

news

AstraZeneca antibody cleared by FDA for preventive use against COVID-19

AstraZeneca's drug, called Evusheld, is the fifth COVID-19 antibody treatment authorized by the FDA, and the fourth now available after Lilly pulled one of its two me...

10 December 2021 news antibody treatment | AstraZeneca

Continue Reading →

news

FibroGen cuts jobs as it weighs anemia drug’s future in US

The upcoming FDA meeting is critical for FibroGen. CEO Enrique Conterno told analysts on a conference call this week that he believes the company has a "good proposal...

15 November 2021 news anemia | AstraZeneca

Continue Reading →

news

AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?

In some ways, AstraZeneca's COVID-19 response has been as good as any in the biopharmaceutical industry. The British drugmaker licensed and developed an effective CO...

15 October 2021 news AstraZeneca | AZD7442

Continue Reading →

news

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials haven't been com...

30 September 2021 news AstraZeneca | Bristol Myers Squibb

Continue Reading →

news

AstraZeneca strikes deal with university spinoff to turn RNA into drugs

The success of the mRNA vaccines developed by Moderna and BioNTech has drawn significant attention, and new funding, to the technology that allows drug developers to ...

30 September 2021 news AstraZeneca | BioNTech

Continue Reading →

news

AstraZeneca reports study success for rare disease drug acquired in Alexion deal

Should detailed study results bear out ALXN1480's benefit and lead to an FDA approval, the experimental drug could become an important new option for people with Wils...

27 August 2021 news Alexion | ALXN1480

Continue Reading →

Current Edition

Upcoming Events

Advertisement

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

AstraZeneca, Daiichi press rivals with new results for breast cancer drug

Amgen partners with Arrakis to develop drugs aimed at RNA

AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug

AstraZeneca antibody cleared by FDA for preventive use against COVID-19

FibroGen cuts jobs as it weighs anemia drug’s future in US

AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

AstraZeneca strikes deal with university spinoff to turn RNA into drugs

AstraZeneca reports study success for rare disease drug acquired in Alexion deal

International Biopharmaceutical Industry